Bangalore, Nov 27, 2009: Sun Pharma said the FDA has granted a tentative approval for an Abbreviated New Drug Application (ANDA) for generic Strattera, atomoxetine hydrochloride capsules.
These atomoxetine hydrochloride capsules, therapeutically equivalent to Strattera capsules from Eli Lilly, are available in seven strengths viz. 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg. Atomoxetine hydrochloride capsules have annual sales of approximately $500 million in the US.
Strattera capsules are indicated for the treatment of attention deficit hyperactivity disorder.
| 
Comment on this article
